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Abstract 
Postural Orthostatic Tachycardia Syndrome (POTS) is a debilitating disease with a commonly non-uniform and 
unspecific presentation that makes diagnosis difficult. A twelve-year-old girl, recently diagnosed with Addison’s Disease, 
was referred to paediatric nephrology for Fludrocortisone-induced nocturnal hypertension. She had fallen off the growth 
curve for both height and weight from the 50th percentile at birth to below the 5th percentile at presentation. The 
severity and multitude of her symptoms, including muscle weakness, poor body control, dizziness, light headedness, 
persistent fatigue, excessive sweating, tachycardia, chronic constipation and recurrent infection hinted at the unusual 
nature of this case of Addison’s. At the time of referral, she had been seen by more than a dozen specialists and 
subspecialists as well as undergone a number of tests including neurophysiological testing without sufficient explanation. 
With the help of tilt-table testing, we established the diagnosis of POTS. There is a lack of tested treatment options for 
POTS, and we established dosing of pyridostigmine in children, based on the emerging literature in adults. While 
pyridostigmine therapy substantially improved her quality of life, it took another 6 years and referral outside the country, 
before a final unifying diagnosis was made. Eventually, the patient was diagnosed with Ehlers Danlos Syndrome with 
associated autonomic dysfunction, including POTS, as well as primary adrenal insufficiency. The parents and the patient 
experienced considerable stress due to the lack of willingness of many physicians that the family encountered to search 
for a diagnosis and a treatment. 
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Intent of this Essay 
 
“About 8% of Canadians, or 3 million individuals, have a 
rare disease. Nearly two-thirds of those with rare diseases 
are children. Canadians have benefitted from public health 
strategies in diabetes, cancer, heart disease and mental 
illness whereas the approach to rare diseases has remained 
fragmented across the country. As a result, Canadian 
families with rare illnesses face extraordinary challenges, 
including misdiagnoses, unnecessary surgeries, social 
isolation, financial hardship, lack of treatment options and 
early death.”1 (Canadian Organization for Rare Disorders) 
 
Unfortunately, the experience of pediatric patients with 
undiagnosed rare diseases remains unfavorable owing to 
the compartmentalized approach inherent to our 
subspecialized system. We present a case of complex 
autonomic dysfunction affecting multiple organ systems 
and leading to debilitating limitations of day-to-day living 
that caused an odyssey through the Tertiary Healthcare 
System and out-of-country referrals before a unifying 
diagnosis and the best possible treatment was found.  The 
purpose is to showcase in this situation that the diagnostic 
workup can be improved and years of meandering through 
the health care system can be avoided.  
 
General Narrative 
 
Our patient is one of the three million individuals in 
Canada inflicted with the misfortune of having a rare 
disease. Born with chronic constipation and plagued with 
recurrent infection and persistent fatigue, the patient and 
her family started on what would prove to be an 
exhaustingly long quest for answers. At the time of 
referral, she had already been seen by more than a dozen 
specialists and subspecialists as well as undergone a 
number of tests including neurophysiological testing 
without a clear diagnosis. As a result of several ER 
admissions for severe bronchitis and pneumonia she was 
labeled with incorrect diagnoses. When seen by GI for her 
chronic constipation, it was suggested she undergo a 
bowel resection, which her parents fortunately refused. 
They believed there was a root cause to all of her suffering 
and were determined to find it.  
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At twelve years of age, the patient was referred to 
paediatric nephrology for Fludrocortisone-induced 
nocturnal hypertension, after having been diagnosed by 
her second paediatric endocrinologist with Addison’s 
Disease. By age twelve, she had fallen off the growth curve 
for both height and weight from the 50th percentile at birth 
to below the 5th percentile (Figure 1). The onset of 
Addison’s Disease was most likely congenital, but 
diagnosis was delayed due to her lack of 
hyperpigmentation, though this symptom may only be 
present in 55% of patients.2 While this initial diagnosis 
explained some of her presentation, the severity and 
multitude of her symptoms, including muscle weakness, 
poor body control, dizziness, light headedness, persistent 
 
Figure 1. Height and weight of our patient against the reference intervals of the Center of Disease Control 
(https://www.cdc.gov/growthcharts/clinical_charts.htm). The target height based on the mid-parental height and 
adjustment for girls was 163 ±10 cm 
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fatigue, excessive sweating, and tachycardia, as well as joint 
hypermobility and excessive dorsiflexion of her fingers  
suggested that this was not a typical case of Addison's 
Disease. The discordance between the severity of her 
symptoms and the availability of objective findings 
characteristic of autonomic dysfunction made for a 
difficult diagnosis, thus our patient was continually passed 
from specialist to specialist as each one exhausted the 
boundaries of their practice.  
 
Eventually, repeated tilt table testing revealed a postural 
heart rate of up to 200 beats per minute, and the diagnosis 
of Postural Orthostatic Tachycardia Syndrome (POTS) 
was assigned; however, it took another 6 years and 
referrals to Dr. Peter Rowe (Johns Hopkins) and Dr. Blair 
Grubb (Toledo, both U.S.A), before a final unifying 
diagnosis was made. Eventually, our patient was diagnosed 
with Ehlers Danlos Syndrome with associated autonomic 
dysfunction, including POTS, as well as cortisol deficiency. 
It is not uncommon for Ehlers Danlos syndrome to be 
associated with autonomic dysfunction,3 nor 
gastrointestinal manifestations.4 In a recent study, 48.6% 
of Ehlers Danlos syndrome patients had postural 
orthostatic tachycardia, 31.4% had orthostatic intolerance 
and only 20% had normal results.3 Unfortunately, there are 
11 known types of Ehlers Danlos syndrome, and often the 
classic features of type I (gravis form) are absent. Some 
authors now consider the association of Ehlers Danlos 
syndrome and autonomous dysfunction a distinct 
subtype.5  
 
After the diagnosis was made, several treatments including 
salt supplements, high fluid intake and Fludrocortisone, 
were tried.  Initially, this significantly reduced her 
symptoms, but they recurred within a matter of months. 
Additional treatment attempts with both clonidine and 
Midodrine were abandoned due of severe side effects. The 
patient’s dose of Fludrocortisone was gradually increased, 
as without it her baseline daytime blood pressure would 
drop to 70/40 mm Hg (50th percentile for a height of 140 
cm 103/60 mm Hg, 5th percentile 85/41 mm Hg).6   
 
This eventually led to the development supine/nocturnal 
hypertension as a side effect of Fludrocortisone, so she 
started on anti-hypertensives at night. At this point, 
Pyridostigmine had been investigated for off-label use in 
adult POTS patients, but no dosing recommendations 
existed for children and the pharmacokinetics had not 
been studied.  To facilitate the trial of this treatment, we 
therefore developed a test for pharmacokinetic monitoring 
using a newly developed semi-automated and specific 
high-performance liquid chromatography/tandem mass 
spectrometry assay and established normal 
pharmacokinetics for children with myasthenia gravis, and 
then applied the learnings to the patient.7 A dose of 60 mg 
resulted in a substantial decrease in the initial tachycardia 
response to upright tilt that persisted in the plateau phase. 
To accommodate the rapid metabolism during childhood, 
the patient received 3 doses over the day with a substantial 
improvement in the quality of life.  
 
Today, at the age of 28, our patient is unrecognizable from 
the frail little girl that walked into our office 15 years ago. 
After completing a Masters and Ph.D. in Physics, she is 
now working as a Post Doc at a major American 
university. With the aid of compression stockings and a 
compression suit, she was able to successfully travel to 
present her Ph.D. research around the globe. She regularly 
walks over 2 kilometers per day thanks to physiotherapy 
and custom orthotics – a huge improvement from the pain 
that exercise used to cause her. 
 
Reflections/Recommendations Based on 
Experience 
 
Throughout this process, apart from the suffering of the 
patient, the family experienced considerable stress due to 
the lack of willingness of many physicians working within 
the framework of a fragmented system to search for an 
appropriate diagnosis that would allow for necessary 
treatment. The family expressed that “So many of the 
physicians we met specialized in a small number of 
conditions and once they ruled those out, were not the 
least concerned about finding the cause of the patient’s 
problems and treating them. This speaks to each specialist 
working in their own silo with no overall owner of [our 
daughter’s] file. The worst part [of our experience] is that 
there is no way to report these kinds of mistakes to the 
system constructively to ensure that the doctors do not 
continue to repeat the same mistakes.” These remarks 
illustrate the severity of the disheartening stress endured 
by the families of paediatric patients with rare and 
unknown diseases in a system limited by the imposition of 
stark and specific boundaries of individual specialists. 
 
Unfortunately, this “diagnostic odyssey” that patients and 
families with rare disorders undergo is actually quite well 
established in the rare disease literature.8 A survey of such 
patients demonstrated that for 25% of participants the 
time to diagnosis was extensive, ranging from 5-30 years, 
and during that time, 40% received an incorrect diagnosis, 
while 50% never received a diagnosis.8 Recently, several 
consortia have advocated the idea that earlier institution of 
whole genome or whole exome sequencing might reduce 
the odyssey by years.9   
 
This patient’s positive outcome would have been 
impossible without this family's perseverance on their long 
search for answers. Unfortunately, not all families are so 
resourceful. Autonomic dysfunction is understudied and 
under-taught, and centers for autonomic dysfunction are 
only now starting to emerge in Canada, at this point only 
for adult patients.10  
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Academic health sciences centres are the last frontier for 
undiagnosed diseases; the last hope for patients that have 
often been through so much despair. We are fortunate to 
work in a country where the governments of the provinces 
acknowledge the need for such research and allow and 
remunerate for a proportion of scholarly activities to help 
patients like ours. Thus, it is our duty to our patients to 
utilize all resources at our disposal for diagnosis and 
treatment. We must not accept the failure to diagnose 
patients with rare diseases. Once we have diagnosed, we 
must not let a lack of tested treatment options resign us to 
inaction. We must not back away from these challenges, 
but instead take the time as doctors to search within a 
much broader framework for the answers our patients 
need. The rewards for doing so, as this patient has taught 
us, can be incredible.  
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